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 CURRENTOPINION Neutralization tiers of HIV-1
David C. Montefioria, Mario Roedererb, Lynn Morrisc,
and Michael S. Seamand
Purpose of review
HIV-1 isolates are often classified on the basis of neutralization ‘tier’ phenotype. Tier classification has
important implications for the monitoring and interpretation of vaccine-elicited neutralizing antibody
responses. The molecular basis that distinguishes the multiple neutralization phenotypes of HIV-1 has been
unclear. We present a model based on the dynamic nature of the HIV-1 envelope glycoproteins and its
impact on epitope exposure. We also describe a new approach for ranking HIV-1 vaccine-elicited
neutralizing antibody responses.
Recent findings
The unliganded trimeric HIV-1 envelope glycoprotein spike spontaneously transitions through at least three
conformations. Neutralization tier phenotypes correspond to the frequency by which the trimer exists in a
closed (tiers 2 and 3), open (tier 1A), or intermediate (tier 1B) conformation. An increasing number of
epitopes become exposed as the trimer opens, making the virus more sensitive to neutralization by certain
antibodies. The closed conformation is stabilized by many broadly neutralizing antibodies.
Summary
The tier 2 neutralization phenotype is typical of most circulating strains and is associated with a
predominantly closed Env trimer configuration that is a high priority to target with vaccines. Assays with tier
1A viruses should be interpreted with caution and with the understanding that they detect many antibody
specificities that do not neutralize tier 2 viruses and do not protect against HIV-1 infection.
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INTRODUCTION
The identification of HIV-1 vaccines that elicit
broadly neutralizing antibodies (bNAbs) will require
reliable information on the ability of vaccine-
elicited antibodies to neutralize diverse strains of
the virus. These antibodies must contend with a
high degree of sequence variability and structural
plasticity in the trimeric envelope glycoproteins
(Env), which mediated virus entry and are the sole
targets for neutralization. Much has been done to
identify suitable reference strains that represent a
spectrum of global Env genetic diversity [1
&
,2–5].
These reference strains are used as Env-pseudotyped
viruses to assess magnitude and breadth of neutrali-
zation in validated reporter gene assays [6–8]. Cri-
teria for reference strain selection places a heavy
emphasis on the neutralization phenotype of the
Envs as determined with serum samples from chron-
ically infected individuals, with the rationale that
the polyclonal nature of the HIV-1-specific antibod-
ies in these sera provides a reasonable sampling
of the spectrum of responses that are possible to
elicit with vaccines. Large cross-sectional datasets
generated withmulticlade panels of Envs and serum
samples have shown that HIV-1 isolates exhibit a
spectrum of neutralization sensitivity that can be
divided into four distinct tiers [9]. Tier 1A is themost
sensitive neutralization phenotype and represents a
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REVIEW
very minor fraction of circulating strains. Tier 1B is
the next most sensitive and represents a larger but
still relatively small fraction of circulating strains.
Most circulating strains exhibit a moderately sensi-
tive tier 2 phenotype that is considered the most
important to target with vaccines; this phenotype
comprises the majority of reference strains. Tier 3 is
the least sensitive phenotype. Many Env immuno-
gens generate antibodies that neutralize tier 1A and
to a lesser extent tier 1B Envs but these antibodies
fail to neutralize most tier 2 and 3 Envs. Impor-
tantly, an ability to neutralize tier 1A does not
predict an ability to neutralize tier 2 Envs [10
&
],
raising questions about the value of tier 1A Env
neutralization as a benchmark for HIV-1 vaccines.
Recent structural studies offer molecular insights
that help explain the spectrum of neutralization
sensitivities the virus exhibits. Other recent work
describes a new classification system to differentiate
the neutralization potency of serum samples and
isolated antibodies. Together this new information
serves as a useful guide for monitoring and inter-
preting neutralizing antibody responses in preclini-
cal and clinical HIV-1 vaccine trials.
EARLY HISTORY: PRIMARY ISOLATES
VERSUS LABORATORY STRAINS
Few strains of HIV-1 were available for laboratory
investigation and as a source of recombinant vac-
cine immunogens in the early years of vaccine
development. These strains (e.g., IIIB/LAV, MN,
SF2) were adapted to replicate in immortalized
CD4þ human cell lines (e.g., H9, CEM) for ease of
production and experimentation. They were classi-
fied as laboratory-adapted or more precisely, T cell
line-adapted (TCLA) viruses to differentiate them
from primary isolates that were passaged only in
human peripheral blood mononuclear cells
(PBMCs). TCLA strains were the sole source of vac-
cine immunogens for many years and were highly
sensitive to neutralization by the antibodies they
induced [11], generating early enthusiasm in the
field. Linear epitopes in the third variable
cysteine-cysteine loop (V3) loop of the surface
gp120 envelope glycoprotein were responsible for
much of this neutralizing activity [12–14], although
epitopes in other regions of gp120 may have con-
tributed in part (e.g., V2, CD4 binding site, corecep-
tor binding site) [15–18]. Indeed, the V3 loop
became known as the principal neutralizing domain
(PND) and amajor focus of early vaccine efforts [19].
The neutralizing activity of early vaccine-
elicited antibodies, combined with their ability to
protect chimpanzees against experimental chal-
lenge with TCLA virus, strengthened the rationale
to move two gp120 subunit vaccines into human
efficacy trails (Vax003 and Vax004) [20]. Neither
vaccine afforded a significant level of protection
[21–23] despite inducing strong neutralizing anti-
body responses against TCLA strains [24–26]. These
early efficacy trials were controversial because
emerging data indicated that primary isolates were
considerably less sensitive to neutralization than
TCLA strains when assayed with HIV-1 sera, linear
V3-specific antibodies [27–29], and sera from phase
1 trials [30–33]. Indeed, peak immune sera from
Vax003 and Vax004 showed only weak neutralizing
activity against primary circulating strains assayed
as Env-pseudotyped viruses [24,26], offering a pos-
sible explanation for why the strong TCLA virus-
specific responses in these trials were nonprotective.
With increasing awareness of the importance of
strain selection came questions about why TCLA
strains and primary isolates were so strikingly differ-
ent in their neutralization phenotype. Early studies
with various combinations of monoclonal antibod-
ies, peptides, Env proteins and mutant viruses indi-
cated that this dichotomy in neutralization
sensitivity is due to differences in epitope exposure
on native trimeric Env spikes [34–37]. For reasons
that are not entirely clear, adaptation to replicate in
transformed cell lines selects viral variants that
exhibit properties consistent with a more open tri-
mer conformation. Thismay also be true for primary
isolates that are cultured for prolonged periods in
the PBMC [38]. Open trimers expose epitopes that
are highly immunogenic in HIV-1-infected individ-
uals and in uninfected recipients of Env vaccines.
Most circulating strains have evolved under pressure
from the host antibody response to conceal these
epitopes by adopting a more closed trimer confor-
mation. Paradoxically, HIV-1 variants that have
replicated and evolved in the host for many weeks
or months prior to the detection of neutralizing
KEY POINTS
 Neutralization tier phenotype as currently defined with
polyclonal HIV-1 sera corresponds to distinct Env
trimer configurations.
 The dynamics of Env trimers on tier 2 HIV-1 isolates
selectively detects neutralizing antibodies that are most
likely to be protective.
 Tier 1A virus neutralization does not predict an ability
to neutralize tier 2 viruses.
 The neutralizing activity of antibodies that only
neutralize tier 1A viruses is nonprotective (some of
these antibodies may have other antiviral properties,
e.g., mediated through Fc receptors).
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antibodies during acute infection are no more sen-
sitive to heterologous HIV-1 sera than chronic iso-
lates [39
&&
,40,41]. Thus, the closed conformation
may be more constant in vivo than it is in vitro in
the absence of neutralizing antibodies. Antibodies
against epitopes on open trimers are likely induced
by nonnative forms of Env, such as unprocessed
gp160 and monomeric gp120 that is shed from
the virus surface [42,43]. Many vaccine immuno-
gens fall into this nonnative category. Closed native
trimers are being sought as immunogens that favor
the induction of bNAbs as a more dominant anti-
body response [44].
Concerns that assays with TCLA strains of virus
could yieldmisleading results led to a growing inter-
est in primary isolates as a higher priority for vaccine
immune monitoring. Early efforts suffered from a
lack of standardization and the absence of a pheno-
typic classification system to confirm the primary
isolate ‘pedigree’ based on neutralization-suscepti-
bility. With improved technologies came a recom-
mendation to utilize Envmolecular clones that were
PCR amplified directly from plasma or PBMC of
infected individuals and assayed as Env-pseudo-
typed viruses [6]. Another recommendation was to
create well characterized Env panels that exhibit a
neutralization phenotype typical of most circulat-
ing strains for use as common reagents across mul-
tiple laboratories [6]. As a result, several panels of
HIV-1 Env reference strains are now available for
standardized assessments of neutralizing antibodies
[1
&
,2–5]. These panels have proven valuable for the
identification and characterization of a new genera-
tion of bNAbs [45,46] and may be an important
benchmark for vaccines.
VIRUS PANELS AND THE TIERED
CATEGORIZATION OF HIV-1
NEUTRALIZATION PHENOTYPES
Early in the process of creating HIV-1 Env-pseudo-
typed reference strains it became apparent that a
major limitation was the lack of objective data to
phenotype and categorize these viruses based on
their overall sensitivity or resistance to antibody-
mediated neutralization. To address this issue, 109
HIV-1 Env pseudotyped viruses representing a broad
range of genetic and geographic diversity were
tested against a similarly diverse set of seven
clade-specific HIV-1 plasma pools derived from
chronically infected individuals [9]. When viruses
were rank-ordered according to average ID50 neu-
tralization titers against the plasma pools, a spec-
trum of sensitivities was observed. Although the
majority of viruses exhibited a relatively narrow
range of average neutralization sensitivity, subsets
of viruses at either end of the spectrum clearly
demonstrated a more sensitive or resistant pheno-
type. Four subsets of viruses representing distinct
tiers of neutralization sensitivity were identified. A
small fraction of isolates that demonstrated a highly
sensitive phenotype were designated tier 1A (3%, all
derived from viruses that were highly passaged in
vitro), and the remaining viruses that exhibited above
average sensitivitywere designated tier 1B (19%). The
majority of viruses clustered into the tier 2 category
(63%), which exhibited average neutralization sensi-
tivity, and tier 3 viruses (15%), which were distin-
guished as having a more neutralization resistant
phenotype. Viruses tended to be more sensitive to
neutralization using clade matched plasma pools
versus clade mismatched pools; however, no associ-
ations were identified between tier categorization
and virus characteristics such as clade, stage of infec-
tion of the individual from whom the Env gene
was cloned (transmitted-founder, acute/early, or
chronic), or the source of virus (plasma, cocultured
PBMC, or uncultured PBMC).
Subsequent studies expanded on the use of
large-scale testing of HIV-1 Env pseudotyped viruses
with chronic HIV-1 plasma samples and bNAbs to
investigate determinants of neutralization sensitiv-
ity and to identify optimal panels of reference
viruses. To identify suitable reference strains repre-
sentative of the global epidemic, deCamp et al. [2]
utilized an exceptionally large checkerboard-style
neutralization data set in which 219 tier 2 and tier
3 Env pseudotyped viruses were assayed with 205
individual chronic HIV-1 plasma samples, where
both the Envs and plasma samples were chosen to
represent the global diversity of HIV-1 clades and
circulating recombinant forms. Using a statistical
model selection procedure known as ‘lasso’, 12 to 9
viruses were selected that accurately captured the
spectrum of neutralizing activity that was observed
with the larger panel of 219 viruses. An additional 3
viruses were selected to increase the clade represen-
tation. All 12 viruses possess a tier 2 neutralization
phenotype (while maintaining a spectrum of aver-
age sensitivities), and exhibit genetic diversity that
includes clades A, B, C and G plus the recombinants
CRF01 and CRF07. This Global Reference Panel of
HIV-1 Env reference strains allows for practical stan-
dardized assessments across various platforms of
HIV-1 vaccines currently under development in
different regions of the world.
A more recent study focused on developing
optimized panels of clade C reference viruses from
southern Africa [39
&&
], a region of the world highly
impacted by the HIV-1 epidemic and where clinical
efficacy studies are being conducted to evaluate
both active and passive immunization strategies.
Hottest topics in HIV infection
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A panel of 200 HIV-1 clade C Envs cloned from
acute/early infections was assembled, and neutrali-
zation tier phenotypes were determined using a
panel of 30 chronic clade C HIV-1 serum samples
that had been preselected to represent a spectrum of
neutralization breadth and potency. K-means clus-
tering analysis of geometric mean ID50 titers dem-
onstrated a similar distribution of tier phenotypes as
had been observed with a multiclade panel of Envs
[9]. The majority of Envs exhibited a moderately
resistant tier 2 phenotype (75%), whereas 1 and
8.5% exhibited sensitive tier 1A and tier 1B pheno-
types, respectively, and 15.5% were classified as
more resistant tier 3 viruses. A comprehensive anal-
ysis of Env traits that impact antibody neutraliza-
tion showed that increases in the length,
glycosylation density, and net negative charge in
the V1–V2 and V4 regions of gp120 are associated
with lower neutralization sensitivity among tier 2
and 3 Envs, similar to what was seen in other studies
[39
&&
,40,47,48]. In addition, an amino acid signature
was identified in which Arg at position 683 in the
membrane-proximal external region was highly
enriched in tier 3 viruses, suggesting that this posi-
tion and region may influence neutralization resis-
tance. The panel of 200 acute/early clade C viruses
was utilized to test the breadth and potency of 15
bNAbs targeting four distinct epitopes on Env that
are considered promising candidates for HIV-1 pre-
vention and treatment. Mathematical modeling was
utilized to predict combinations of bNAbs that
would complement one another for the most
effective coverage against clade C viruses, taking
into account potency, breadth, extent of complete
neutralization, and instantaneous inhibitory
potential [49
&
].
While the extended panel of 200 acute/early
clade C viruses enabled large-scale studies to
robustly interrogate genotypic properties that
impact antibody recognition and neutralization
sensitivity, smaller panels of more practical size
are needed for high-throughput screening of serum
samples from clinical vaccine studies or characteriz-
ing newly isolated bNAbs. To this end, Hraber et al.
[1
&
] used hierarchical clustering of bNAb neutraliza-
tion titers and magnitude-breadth distributions
against the 200 virus panel to down-select optimal
panels of either 100 or 50 viruses that exhibit a high
degree of overlap with the larger virus panel for all
15 bNAbs tested. These smaller panels allow for
more rapid detailed characterization of the breadth
and potency of newly isolated bNAbs or potent
immune sera, and should reflect the range of virus
sensitivities that would be observed with the larger
200 virus panel. To facilitate high-throughput
screening of vaccine-sera from large-scale clinical
trials, a smaller, more manageable panel of
12 early/acute clade C viruses was also selected via
computational guidance to represent the diverse
neutralization sensitivity patterns observed with
both polyclonal plasma andmonoclonal antibodies.
This panel is intended to detect relatively weak or
potentially clade-specific tier 2 neutralization
responses, which will facilitate the screening of
vaccine sera in regions where clade C infections
predominate and clade C vaccines are being tested.
Together these studies demonstrate how large-scale
tier phenotyping data informed the design of opti-
mized and complementary virus panels for the eval-
uation of candidate HIV-1 vaccines and bnAbs.
MOLECULAR INSIGHTS INTO THE TIERED
NEUTRALIZATION PHENOTYPES OF HIV-1
VIRUSES
Native HIV-1 Env on the virus surface consists of a
trimolecular complex of gp120-gp41 heterodimers
that mediate virus entry through sequential binding
of gp120 to CD4 and a coreceptor, most often CCR5,
followed by gp41 activation and membrane fusion
[50]. Studies of soluble native-like Env trimers (e.g.,
SOSIPs) using a combination of x-ray crystallogra-
phy, cryo-electron microscopy/tomography and
hydrogen–deuterium exchange have provided
detailed structural information on the prefusion
form of the closed trimer and the substantial con-
formational changes that take place uponCD4 bind-
ing that lead to outward rotation of gp120
protomers, greater exposure of the V3 loop and
formation of the coreceptor binding region [51–
58]. Amore recent study characterized the antigenic
properties of soluble trimers and corresponding
gp120 monomers from a tier 3 strain of HIV-1
(CH120.6) and found that many epitopes for non-
neutralizing and tier 1 virus-neutralizing antibodies
on the gp120 were occluded on the trimers [59
&&
].
Consistent with earlier reports [34–37], these
combined observations point to a structure-based
explanation for the different neutralization tier
phenotypes of HIV-1.
Whereas the above studies used soluble liganded
trimers to characterize the open conformation, a
separate study used single-molecule fluorescence res-
onance energy transfer (smFRET) of virion-associated
Env to interrogate spontaneous transitions in the
configuration of unliganded trimers [60
&&
]. Two
strains of trimers were examined, one from a tier 2
virus (JR-FL) and another froma tier 1A virus (NL4-3).
Both trimers exhibited spontaneous and reversible
conformational changes, with three major confor-
mations identified: closed, open, and intermediate
(Fig. 1). Transitions were seen between the closed
Neutralization tiers of HIV-1 Montefiori et al.
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and open states and between the intermediate and
open states but rarely between closed and intermedi-
ate states. Soluble CD4 stabilized the open confor-
mation of NL4-3 whereas CD4 þ 17b (a coreceptor
mimic) and 17b alone stabilized the intermediate
conformation of this trimer. CD4 and CD4þ 17b
stabilized both the open and intermediate conforma-
tion of JR-FL equally well but here 17b alone had no
effect. Together these observations indicate that the
open conformation corresponds to the CD4-bound
state, whereas the intermediate conformation corre-
sponds to the CD4/coreceptor-bound state. Also, the
coreceptor binding site is more occluded on JR-FL
(tier 2) than NL4-3 (tier 1A). Open trimers that are
stabilized by ligation would only exist at the virus–
cell interface,where they are relatively inaccessible to
antibodies. Many bNAbs stabilize the closed state
[54,57,60
&&
,61], which may contribute to entry-
inhibiting activity.
Equilibrium in the structural dynamics of HIV-1
Env trimers provides the necessary balance between
entry fitness and immune evasion but also appears
to give rise to the neutralization tier phenotypes. As
illustrated in Fig. 1, Env trimers on tier 2 viruses
spend more time in a closed conformation, which is
a target for bNAbs and autologous NAbs but few
other Env-specific antibodies. Trimers on tier 1A
viruses spend more time in an open conformation,
providing access to many epitopes that are occluded
on tier 2 Envs. By analogy, trimers on tier 1B viruses
may spend more time in an intermediate conforma-
tion that partially exposes epitopes. Thus, the degree
of openness distinguishes the tiers and is quantifi-
able on the basis of the neutralization potency of
antibodies to epitopes that are occluded on the
closed trimer.
RECOMMENDATIONS ON THE USE OF
TIERED REFERENCE STRAINS FOR
VACCINE EVALUATION
A major goal of HIV-1 vaccine development is the
induction of antibodies able to broadly neutralize
tier 2 viral strains. Most experimental HIV-1 vac-
cines to date have only been able to elicit antibodies
that neutralize tier 1A and a subset of tier 1B viruses,
which represent a minor fraction of circulating
strains. Though some success has been made at
generating antibodies that neutralize vaccine-
matched tier 2 strains through the use of native-like
V1V2 V3
Tier 2
Tier 1A
Tier 1B
IntermediateOpenClosed
FIGURE 1. Balance of conformational states in the HIV-1 Env trimer. Shown is a model based on the findings of Munroe et al.
[60&&] and also proposed by Cai et al. [59&&]. Native Env trimers on the virus surface are structurally dynamic and constantly
transitioning between at least three conformations that differentially expose a variety of epitopes for nonbNAbs. Env trimers on
tier 2 viruses predominantly occupy a closed conformation that masks nonbNAb epitopes. Env trimers on tier 1A viruses
frequently transition to an open conformation that exposes these epitopes, making the viruses highly sensitive to neutralization
by polyclonal HIV-1 sera and many current vaccine-elicited antibodies. Tier 1B viruses may spend relatively more time in an
intermediate conformation that partially exposes these epitopes.
Hottest topics in HIV infection
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trimeric Envs, these antibodies have very little activ-
ity against heterologous tier 2 strains and thus are
not broadly neutralizing [62–64].
As mentioned earlier, the Vax003 and Vax004
trials demonstrated that potent tier 1A virus neu-
tralizing antibodies were unable to provide protec-
tion from HIV-1 infection [25,26]. Although the
moderate efficacy in another phase 3 trial, RV144,
was not linked to neutralizing activity, tier 1A virus
neutralization was identified as a secondary corre-
late when the IgA fraction was removed [65]. In
chronic HIV-1 infection, antibodies able to neutral-
ize tier 1A viruses have been shown to exert some
selection pressure against autologous viruses, and
mAb isolation confirmed that they target epitopes
in V3 and the CD4 binding site (CD4bs) [66]. Fur-
thermore, in the setting of mother-to-child infec-
tion where viruses are shared, antibodies that target
the V3were shown to correlate with a reduced risk of
HIV-1 transmission [67,68
&
]. Thus, while there is
evidence that tier 1A virus neutralizing activity
has some potential for protection, the impact is
likely to be limited. The prevention of sexual HIV-
1 transmission will likely require an ability to neu-
tralize tier 2 viruses.
Tier 1A viruses continue to be used for immune
monitoring in preclinical and human clinical trials
despite a paucity of evidence that they are indicators
of a desirable response. Moreover, their continued
use has potential to create confusion over the goals
for HIV-1 vaccines. In 2016, the Global HIV Vaccine
Enterprise convened a workshop to discuss the mer-
its of tier 1A viruses and whether it was time to
‘break an old habit’ by discontinuing their use alto-
gether. It was noted that assessments with tier 1A
viruses can provide an indication of the overall
immunogenicity of a vaccine, for example, by show-
ing increased antibody titers following boosting
with protein vaccines [69]. These titers also enable
general comparison between different vaccines and
different regimens as well as the durability of anti-
body responses, much the same as binding antibody
assays. It was recommended that tier 1A viruses
could be used on a limited basis for these types of
observations to be made, with the understanding
that an ability to neutralize only these viruses
is unlikely to protect against infection, or to be
an early indicator of progress toward tier 2 virus
neutralization.
Questions were raised at the workshop concern-
ing the possibility that tier 1B virus neutralization
might be an indicator of early progress toward tier 2
virus neutralization. Although these viruses are
more sensitive to neutralization compared to tier
2 viruses, most are resistant to V3 and weak mAbs,
confirming they are antigenically distinct from tier
1A viruses [9]. Studies that have used tier 1B viruses
to monitor vaccine responses have shown titers to
be at least 10-fold lower compared with those
against tier 1A viruses [70,71]. The kinetics of tier
1B responses also differed from those against tier 1A
viruses and in some cases, tier 1B virus neutraliza-
tion was not inhibited by V3 peptides [72,73].
Furthermore, tier 1B virus neutralizing titers track
with tier 2 rather than tier 1A virus neutralizing
titers [74] suggesting they share an Env trimer
configuration that more closely resembles tier 2.
Immunization experiments using a SOSIP.664 tri-
mer made from a tier 1B isolate, AMC008 showed
that it induced autologous virus neutralizing anti-
bodies and minimal tier 1A virus neutralizing anti-
bodies, similar to other SOSIP proteins [64]. This
suggested that once stabilized, Env from tier 1B
resemble those made using tier 2 Envs. As men-
tioned above, the increased sensitivity of tier 1B
viruses to certain antibodies is likely explained by
the more frequent sampling of an open conforma-
tion compared to tier 2 viruses. Because tier 1B
viruses are diverse, spanning a range of neutrali-
zation sensitivities, it may be possible to identify a
panel of tier 1B viruses that have greater value
than tier 1A for immune monitoring.
NEUTRALIZATION POTENCY SCORES FOR
SERUM AND MONOCLONAL ANTIBODIES
Decisions on which vaccine (or prophylactic passive
immunization) strategies should be prioritized for
development and large-scale testing are made on a
variety of criteria. One of the most important is
based on a comparison of the breadth of neutraliza-
tion that can be elicited. However, there is no simple
way to do this. For example, is a mAb that neutral-
izes a minority of tier 3 virus and a large majority of
tier 2 viruses preferable to one that neutralizes half
of each category? Trying to compare the distribu-
tions of neutralization breadths across two arms of a
clinical trial (e.g. phase 1 comparing two different
vaccines) is even more difficult.
Hraber et al. [75
&&
] devised a metric by which
antisera or antibodies can be compared in order to
inform these decisions in an objective manner. This
metric can be calculated using an on-line tool
(http://hiv.lanl.gov/content/sequence/NI/ni.html).
In essence, the output of the calculation is a ‘neu-
tralization potency’ that is scaled to be similar to the
tier values of viruses. For example, a neutralization
potency value of 1 indicates that the antisera neu-
tralizes only tier 1-like viruses; a neutralization
potency value of 1 indicates an antiserum that
can neutralize at least some tier 3 viruses. Because
the neutralization potency is a continuous metric, it
Neutralization tiers of HIV-1 Montefiori et al.
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can be used to compare elicited antisera and rank
potential vaccine candidates accordingly.
The metric is based on a logistic regression of
neutralization (yes/no) at a single dilution of anti-
sera, against a set of viruses. Given the current
standard of performing the neutralization assay at
eight dilutions, this makes the proposed use of
neutralization potency more suitable to high-
throughput measurements. Given the logistical
and economic constraints of requiring eight dilu-
tions per virus, it has been proposed to use a subset
of12 viruses from the large panel ofmore than 200
that can provide a reasonable estimate of breadth
[1
&
,2]. The same has been done for the neutraliza-
tion potency metric; alternatively, a much larger set
of viruses can be tested in the single-dilution format
to achieve a more precise breadth score.
Finally, the logistic regression of the neutraliza-
tion data provides not only the neutralization
potency value (related to breadth), but also a ‘slope’
value. The slope indicates how much the neutrali-
zation potency of the antisera depends on the neu-
tralization resistance (tier) of tested viruses. In the
case of monoclonal antibodies, this dependence is
typically very low, i.e., the neutralization of a bNAb
depends primarily on the presence or absence of the
epitope (which is itself not usually correlated to tier
category). Hraber et al. [75
&&
] suggest that the slope
value of antisera may indicate how polyepitopic the
dominant neutralization response is, and that anti-
sera that are primarily directed against a single
epitope can be distinguished from antisera that
neutralize throughmultiple epitopes. Thus, the neu-
tralization potency analysis might provide another
discriminatory metric by which vaccine strategies
can be objectively and quantitatively compared.
CONCLUSION
The neutralization tier phenotypes of HIV-1 isolates
can be understood in the context of the dynamic
nature of Env trimers on the virus surface. These
trimers spontaneously transition between closed,
open, and at least one intermediate conformation,
whereopen trimers exposemoreepitopes thanclosed
trimers. Natural variation in transition time influen-
ces the neutralization phenotype of the virus, where
Env trimers that spendmore time in a closed confor-
mation display a tier 2 phenotype, while those that
spendmore time in the open conformation display a
tier 1 phenotype. Other structural features of Env
contribute to the spectrum in neutralization-sensi-
tivity seenwithin the tier 2 category of viruses. A new
neutralization potency score utilizes this variation to
quantitatively compare serum antibody responses
and monoclonal antibodies.
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